Mathew Pletcher

Mathew Pletcher serves as the Chief Scientific Officer at Weaver Biosciences since July 2024. Pletcher is a Co-Founder and Board Member of the RDH12 Fund for Sight and has been involved since October 2010. Additionally, Pletcher holds board member positions at Odylia Therapeutics and 64x Bio, and serves as a Scientific Advisory Board Member at 64x Bio since April 2023. Pletcher is also an Adjunct Assistant Professor at the University of North Carolina at Chapel Hill since December 2016. Previous roles include Chief Scientific Officer at Kisbee Therapeutics, Senior Vice President at Astellas Gene Therapies, and various leadership positions at Roche and Autism Speaks. Pletcher's academic credentials include a PhD in Human Genetics from The Johns Hopkins University School of Medicine and a Bachelor of Science in Biology from Duquesne University.